Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

New drug shows impressive results against lipoprotein(a), a genetic form of cholesterol that affects millions but remains ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

High levels of a chemical that is believed to be behind sudden and inexplicable heart attacks and strokes could soon have ...

34,734 people played the daily Crossword recently. Can you solve it faster than others?34,734 people played the daily Crossword recently. Can you solve it faster than others?

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting ...

An estimated 64 million Americans have elevated levels of lipoprotein(a), or Lp(a), a type of cholesterol that can increase the risk of heart attack and other cardiovascular problems. Having high ...

UVA professor Dr. Christopher Kramer explains how a new Eli Lilly drug may cut a significant heart attack risk factor by 95%.

Verve shares Phase 1b results of VERVE-102, showing dose-dependent LDL-C reductions and strong safety in patients with HeFH ...